Founder financial model
See the founder journey before you bet your clinical income.
Choose your startup type. See the usual path from idea to meaningful company value. Understand who might fund each stage, what they ask for, how your ownership changes, what risk gets retired, and what the expected financial outcome looks like compared with clinical income.
Startup type selector
Class III device
Capital-intensive path where animal work, IDE, pivotal data, and PMA readiness drive most of the value step-up.
- Regulatory burden
- Capital intensity
- Time to revenue
- Likely funders
- Main value points
- Common failure modes
Founder journey arc
From clinical idea to fundable company.
The arc shows how a clinician's idea becomes more fundable as specific risks are retired. Each step names what has been proven, why that proof can increase company value, what capital is usually needed to reach the step, and how much lead-founder ownership may remain after that financing. If the company exits through acquisition or IPO at any point, the ownership shown for that step is the stake that matters for founder proceeds.
Capital stack and dilution
Who owns the company at the modeled exit point.
This table is the modeled cap table at the exit point for the selected path. The founder does not give up ownership because value rises; ownership falls when the company raises outside capital to reach the next value step. If the company exits by acquisition or IPO after a step, the relevant founder stake is the ownership remaining at that moment.
| Holder | Typical role | Modeled exit ownership |
|---|
Expected outcome range
Most doctors should not quit the day job too early.
Expected value is the size of a possible outcome multiplied by the probability of reaching it. A company might have a large possible exit, but if the chance of funding, survival, and acquisition is low, the probability-adjusted founder value can still be smaller than the clinical income put at risk. The calculator below makes that tradeoff visible before the founder changes clinical work, raises capital, or spends heavily on the wrong next step.
Typical planning range
Class III device typical planning range
Under typical assumptions, expected founder value is roughly $0.2M-$2.6M, compared with $1.2M-$1.8M of clinical income at risk.
A health tech startup is not one big bet. It is a sequence of expensive risk-retirement steps. Each step can increase company value, but usually requires capital, dilution, time, and clinical opportunity cost. If the company exits after a given step, the relevant ownership is the stake remaining after the raises required to reach that step.
Edit assumptions manually
Change the inputs if your case is stronger or weaker than the planning range.
This does not beat clinical income on expected value. Pursue only if the mission matters and you can limit downside.
With these assumptions, the expected financial value is far below the clinical income at risk. Keep clinical work in the plan and use structured help to lower wasted motion.
Educational founder financial model only. Not financial, legal, regulatory, medical, or investment advice. The model uses conservative planning estimates layered on public benchmarks; it does not predict fundraising success, exit timing, exit probability, or whether a founder should leave clinical work.
Founder math sources: PitchBook-NVCA 2025 Venture Monitor for median round sizes and valuation context by series; Carta dilution analysis for dilution pressure across rounds; SVB Healthcare Investments and Exits for healthcare exit framing; Rock Health digital health funding for digital health funding and M&A context.
Stage-gate sources: FDA device classification, FDA IDE approval process, FDA 510(k) submission process, FDA CDS guidance, FDA SaMD resources, HHS HIPAA Security Rule, and AICPA SOC 2 Trust Services Criteria.